Article: The UK’s Cannabis Paradox: Leading Global Exports Amid Domestic Restrictions | Cannabis Law Report | Where to buy Skittles Moonrock online
Learn where to order CBD online. TOP QUALITY GRADE A++
Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.
👉 Click here to Visit our shop! 🛒
The United Kingdom currently holds the paradoxical position of being the world’s largest producer and exporter of legal cannabis for medical and scientific purposes, yet domestically, cannabis use remains strictly regulated and largely inaccessible to its citizens.
This contradiction highlights a complex situation where economic opportunity and healthcare innovation coexist with stringent prohibitionist policies.
The UK is Already a Global Leader in Legal Cannabis Production
According to reports by the International Narcotics Control Board (INCB), the UK has consistently led global figures in cannabis production for medical and scientific use. Back in 2016, the UK produced approximately 95 tonnes of legal cannabis, which was more than double the previous year’s total. This remarkable growth has continued, and by 2021, production dramatically rose to over 329 tonnes, making the UK responsible for approximately 43% of global medical cannabis production.
This significant output is primarily intended for export, meeting international demands in markets where cannabis-based treatments are widely accepted and legally accessible. The economic benefits derived from this sector position the UK as a leader in medical cannabis innovation and distribution on the world stage.
Limited Domestic Access to Medical Cannabis
Despite its significant role as a global cannabis supplier, the UK presents a dramatically different picture domestically. Medical cannabis was officially legalized in November 2018, sparked largely by public campaigns surrounding high-profile patient cases, such as children with treatment-resistant epilepsy.
However, this landmark decision has yet to translate into widespread accessibility. NHS prescriptions for medical cannabis remain exceedingly rare. In 2019 it was reported that only 18 prescriptions for unlicensed cannabis-based products were dispensed in England. This is due primarily to stringent NHS guidelines that limit prescriptions predominantly to patients suffering from severe epilepsy, multiple sclerosis-related spasticity, and chemotherapy-induced nausea. Consequently, the vast majority of patients requiring medical cannabis products have to resort to private healthcare services, incurring high out-of-pocket expenses.
Read full article
Leave a Reply
Want to join the discussion?Feel free to contribute!